Pain	pain	O	DISEASE	OTHERS	I
responses	responses	O	O	O	O
in	in	O	O	O	O
methadone-maintained	methadone-maintained	O	O	O	O
opioid	opioid	O	O	O	O
abusers	abusers	O	O	O	O
.	.	O	O	O	O

Providing	providing	O	O	O	O
pain	pain	O	DISEASE	OTHERS	I
management	management	O	O	O	O
for	for	O	O	O	O
known	known	O	O	O	O
opioid	opioid	O	O	O	O
abusers	abusers	O	O	O	O
is	is	O	O	O	O
a	a	O	O	O	O
challenging	challenging	O	O	O	O
clinical	clinical	O	O	O	O
task	task	O	O	O	O
,	,	O	O	O	O
in	in	O	O	O	O
part	part	O	O	O	O
because	because	O	O	O	O
little	little	O	O	O	O
is	is	O	O	O	O
known	known	O	O	O	O
about	about	O	O	O	O
their	their	O	O	O	O
pain	pain	O	DISEASE	OTHERS	I
experience	experience	O	O	O	O
and	and	O	O	O	O
analgesic	analgesic	O	O	O	O
requirements	requirements	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
study	study	O	O	O	O
was	was	O	O	O	O
designed	designed	O	O	O	O
to	to	O	O	O	O
describe	describe	O	O	O	O
pain	pain	O	DISEASE	OTHERS	I
tolerance	tolerance	O	O	O	O
and	and	O	O	O	O
analgesic	analgesic	O	O	O	O
response	response	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
sample	sample	O	O	O	O
of	of	O	O	O	O
opioid	opioid	O	O	OTHERS	I
addicts	addicts	O	O	OTHERS	I
stabilized	stabilized	O	O	O	O
in	in	O	O	O	O
methadone-maintenance	methadone-maintenance	O	O	O	O
(	(	O	O	O	O
MM	mm	O	O	OTHERS	I
)	)	O	O	O	O
treatment	treatment	O	O	O	O
(	(	O	O	O	O
n	n	O	O	OTHERS	I
=	=	O	O	O	O
60	60	O	O	O	O
)	)	O	O	O	O
in	in	O	O	O	O
comparison	comparison	O	O	O	O
to	to	O	O	O	O
matched	matched	O	O	O	O
nondependent	nondependent	O	O	O	O
control	control	O	O	O	O
subjects	subjects	O	O	O	O
(	(	O	O	O	O
n	n	O	O	OTHERS	I
=	=	O	O	O	O
60	60	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

By	by	O	O	O	O
using	using	O	O	O	O
a	a	O	O	O	O
placebo-controlled	placebo-controlled	O	O	O	O
,	,	O	O	O	O
two-way	two-way	O	O	O	O
factorial	factorial	O	O	O	O
design	design	O	O	O	O
,	,	O	O	O	O
tolerance	tolerance	O	O	O	O
to	to	O	O	O	O
cold-pressor	cold-pressor	O	O	O	O
(	(	O	O	O	O
CP	cp	O	O	OTHERS	I
)	)	O	O	O	O
pain	pain	O	DISEASE	OTHERS	I
was	was	O	O	O	O
examined	examined	O	O	O	O
,	,	O	O	O	O
both	both	O	O	O	O
before	before	O	O	O	O
and	and	O	O	O	O
after	after	O	O	O	O
oral	oral	O	O	O	O
administration	administration	O	O	O	O
of	of	O	O	O	O
therapeutic	therapeutic	O	O	O	O
doses	doses	O	O	O	O
of	of	O	O	O	O
common	common	O	O	O	O
opioid	opioid	O	O	O	O
(	(	O	O	O	O
hydromorphone	hydromorphone	O	O	OTHERS	I
2	2	O	O	O	O
mg	mg	O	O	OTHERS	I
)	)	O	O	O	O
and	and	O	O	O	O
nonsteroidal	nonsteroidal	O	O	O	O
anti-inflammatory	anti-inflammatory	O	O	O	O
(	(	O	O	O	O
ketorolac	ketorolac	O	O	OTHERS	I
10	10	O	O	O	O
mg	mg	O	O	OTHERS	I
)	)	O	O	O	O
analgesic	analgesic	O	O	O	O
agents	agents	O	O	O	O
.	.	O	O	O	O

Results	results	O	O	O	O
showed	showed	O	O	O	O
that	that	O	O	O	O
MM	mm	O	O	OTHERS	I
individuals	individuals	O	O	O	O
were	were	O	O	O	O
significantly	significantly	O	O	O	O
less	less	O	O	O	O
tolerant	tolerant	O	O	O	O
of	of	O	O	O	O
CP	cp	O	O	OTHERS	I
pain	pain	O	DISEASE	OTHERS	I
than	than	O	O	O	O
control	control	O	O	O	O
subjects	subjects	O	O	O	O
,	,	O	O	O	O
replicating	replicating	O	O	O	O
previous	previous	O	O	O	O
work	work	O	O	O	O
.	.	O	O	O	O

Analgesic	analgesic	O	O	O	O
effects	effects	O	O	O	O
were	were	O	O	O	O
significant	significant	O	O	O	O
neither	neither	O	O	O	O
for	for	O	O	O	O
medication	medication	O	O	O	O
nor	nor	O	O	O	O
group	group	O	O	O	O
.	.	O	O	O	O

These	these	O	O	O	O
data	data	O	O	O	O
indicate	indicate	O	O	O	O
that	that	O	O	O	O
MM	mm	O	O	OTHERS	I
opioid	opioid	O	O	O	O
abusers	abusers	O	O	O	O
represent	represent	O	O	O	O
a	a	O	O	O	O
pain-intolerant	pain-intolerant	O	O	O	O
subset	subset	O	O	O	O
of	of	O	O	O	O
clinical	clinical	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

Their	their	O	O	O	O
complaints	complaints	O	O	O	O
of	of	O	O	O	O
pain	pain	O	DISEASE	OTHERS	I
should	should	O	O	O	O
be	be	O	O	O	O
evaluated	evaluated	O	O	O	O
seriously	seriously	O	O	O	O
and	and	O	O	O	O
managed	managed	O	O	O	O
aggressively	aggressively	O	O	O	O
.	.	O	O	O	O

